David W. Gryska - 27 Aug 2026 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Reporting relationship: Director
Issuer ticker: FBRX
Reported as of: 27 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Aug 2026, 16:33:05 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact

Key filing fact

David W. Gryska filed Form 4 for Forte Biosciences, Inc. (FBRX) on 27 Aug 2026.

Key facts

This page summarizes David W. Gryska's Form 4 filing for Forte Biosciences, Inc. (FBRX).
5 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 27 Aug 2026, 16:33.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001202335 Primary reporting owner

GRYSKA DAVID W

Relationship: Director
Address: C/O FORTE BIOSCIENCES, INC., 3060 PEGASUS PARK DR., BUILDING 6, DALLAS
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Signature date: 27 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FBRX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -5,940
Change %: -100%
Price
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FBRX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -2,000
Change %: -100%
Price
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000
Exercise price: $25.50
Footnotes: F2

FBRX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,000
Change %: -100%
Price
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000
Exercise price: $20.00
Footnotes: F2

FBRX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -31,000
Change %: -100%
Price
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,000
Exercise price: $7.54
Footnotes: F2

FBRX transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -18,353
Change %: -100%
Price
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,353
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David W. Gryska is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

Footnote F2

Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

Footnote F4

Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.